David and Chamath discuss the potential impact of a minimum tax on tax breaks and the prescription drug price cap in the new bill. They explore the potential adverse effects on incentives and reduced spending on new drug development, while also acknowledging the need for government negotiation and the potential for increased costs in certain sectors.
